Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD30-DM1
- Development stage
- Phase 1
- Lead developer
- Shanghai Cross-linked Pharmaceutical Research and Development
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CD30-DM1 is an antibody-drug conjugate (ADC) designed to treat CD30-positive hematological malignancies, such as Hodgkin lymphoma, anaplastic large cell lymphoma, and cutaneous T-cell lymphoma. It consists of an anti-CD30 chimeric monoclonal antibody (cAC10) conjugated via a stable SMCC linker to DM1 (mertansine or emtansine), a potent maytansinoid derivative. The antibody component specifically targets and binds to the CD30 antigen expressed on cancer cells. Upon internalization, the DM1 payload is released intracellularly, where it acts as a microtubule inhibitor, disrupting microtubule assembly, leading to cell cycle arrest and ultimately inducing apoptosis in the cancer cells. The drug was initially developed by Shanghai Jiaolian Drug Development Co., Ltd. and subsequently acquired by Shanghai Pharmaceuticals.
- Other names
- CD30-MCC-DM1CD-30-MCC-DM1CD 30-MCC-DM1anti-CD30/DM1 antibody-drug conjugate F0002
02
Targets
TUBB (Tubulin (alpha and beta subunits))CD30 (CD30 antigen)
Beyond the preview
Go deeper on CD30-DM1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD30-DM1.